224 related articles for article (PubMed ID: 19503102)
61. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
62. Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase.
Xiao X; Su G; Brown SN; Chen L; Ren J; Zhao P
J Nutr Biochem; 2010 Jul; 21(7):621-6. PubMed ID: 19570670
[TBL] [Abstract][Full Text] [Related]
63. [A comparative study of cardiac function in transgenic hypertensive rats, in spontaneously hypertensive rats and in normotensive rats].
Bohlender J; Hildenbrand U; Schlegel WP; Hempel P; Nissen E; Krause EG; Bartel S
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):993-6. PubMed ID: 10989744
[TBL] [Abstract][Full Text] [Related]
64. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
Sun L; Ke Y; Zhu CY; Tang N; Tian DK; Gao YH; Zheng JP; Bian K
Chin Med J (Engl); 2008 Nov; 121(22):2305-11. PubMed ID: 19080338
[TBL] [Abstract][Full Text] [Related]
65. Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure.
Morgan EE; Rennison JH; Young ME; McElfresh TA; Kung TA; Tserng KY; Hoit BD; Stanley WC; Chandler MP
Am J Physiol Heart Circ Physiol; 2006 May; 290(5):H1899-904. PubMed ID: 16339830
[TBL] [Abstract][Full Text] [Related]
66. Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
Mervaala EM; Malmberg L; Teräväinen TL; Laakso J; Vapaatalo H; Karppanen H
Br J Pharmacol; 1998 Jan; 123(2):195-204. PubMed ID: 9489606
[TBL] [Abstract][Full Text] [Related]
67. Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone.
Henderson BC; Sen U; Reynolds C; Moshal KS; Ovechkin A; Tyagi N; Kartha GK; Rodriguez WE; Tyagi SC
Int J Biol Sci; 2007 Sep; 3(6):385-92. PubMed ID: 17848984
[TBL] [Abstract][Full Text] [Related]
68. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Tureyen K; Kapadia R; Bowen KK; Satriotomo I; Liang J; Feinstein DL; Vemuganti R
J Neurochem; 2007 Apr; 101(1):41-56. PubMed ID: 17394460
[TBL] [Abstract][Full Text] [Related]
69. Targeting Peroxisome Proliferator Activated Receptor α (PPAR α) for the Prevention of Mitochondrial Impairment and Hypertrophy in Cardiomyocytes.
Kar D; Bandyopadhyay A
Cell Physiol Biochem; 2018; 49(1):245-259. PubMed ID: 30138942
[TBL] [Abstract][Full Text] [Related]
70. Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.
Peng H; Carretero OA; Alfie ME; Masura JA; Rhaleb NE
Hypertension; 2001 Mar; 37(3):974-80. PubMed ID: 11244026
[TBL] [Abstract][Full Text] [Related]
71. Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.
Wang X; Liu X; Zhan Y; Lavallie ER; Diblasio-Smith L; Collins-Racie L; Mounts WM; Rutkowski JL; Xu X; Goltsman I; Abassi Z; Winaver J; Feuerstein GZ
J Pharmacol Exp Ther; 2010 Sep; 334(3):820-9. PubMed ID: 20519551
[TBL] [Abstract][Full Text] [Related]
72. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.
Ogawa T; Linz W; Stevenson M; Bruneau BG; Kuroski de Bold ML; Chen JH; Eid H; Schölkens BA; de Bold AJ
Circulation; 1996 Jun; 93(11):2059-67. PubMed ID: 8640983
[TBL] [Abstract][Full Text] [Related]
73. Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat.
Ismael S; Purushothaman S; Harikrishnan VS; Nair RR
Mol Cell Biochem; 2015 Aug; 406(1-2):173-82. PubMed ID: 25976666
[TBL] [Abstract][Full Text] [Related]
74. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure.
Liu YH; Xu J; Yang XP; Yang F; Shesely E; Carretero OA
Hypertension; 2002 Feb; 39(2 Pt 2):375-81. PubMed ID: 11882576
[TBL] [Abstract][Full Text] [Related]
75. Rosiglitazone attenuates myocardial remodeling in spontaneously hypertensive rats.
Ti Y; Hao MX; Li CB; Wang ZH; Hou XY; Zhao XQ; Liu JN; Zhang W; Zhang Y; Bu PL
Hypertens Res; 2011 Mar; 34(3):354-60. PubMed ID: 21248758
[TBL] [Abstract][Full Text] [Related]
76. Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats.
Yazawa H; Miyachi M; Furukawa M; Takahashi K; Takatsu M; Tsuboi K; Ohtake M; Murase T; Hattori T; Kato Y; Murohara T; Nagata K
J Card Fail; 2011 Dec; 17(12):1041-50. PubMed ID: 22123369
[TBL] [Abstract][Full Text] [Related]
77. Influence of age and dietary sodium on the cardiovascular and renal effects of ramipril in spontaneously hypertensive rats.
Teräväinen TL; Mervaala EM; Pörsti I; Laakso J; Vapaatalo H; Karppanen H
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):311-21. PubMed ID: 9379779
[TBL] [Abstract][Full Text] [Related]
78. Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats.
Shinzato T; Ohya Y; Nakamoto M; Ishida A; Takishita S
Hypertens Res; 2007 Sep; 30(9):863-73. PubMed ID: 18037780
[TBL] [Abstract][Full Text] [Related]
79. Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.
Burrell LM; Burchill L; Dean RG; Griggs K; Patel SK; Velkoska E
Exp Physiol; 2012 Apr; 97(4):477-85. PubMed ID: 22198016
[TBL] [Abstract][Full Text] [Related]
80. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
